You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

Guidelines & Advice
About Guidelines Email Guidelines Team

Neoadjuvant or Adjuvant Therapy for Resectable Gastric Cancer

Version: 3 ID: 2-14 Apr 2011
Type of Content: Guidelines & Advice, Clinical
Document Status: Archived
Authors:
G. Knight, C.C. Earle, R. Cosby, N. Coburn, Y. Youssef, K. Spithoff, R. Malthaner, R.K.S. Wong, Gastrointestinal Cancer Disease Site Group

Patient Population

Adult patients with potentially curable, surgically resectable (Stage 1B [invasion of the muscularis propria] and above) gastric cancer.

Intended Guideline Users

Clinicians and healthcare providers involved in the management and referral of patients with resectable gastric cancer.

Research Question(s)

Should patients with resectable gastric cancer (Stage 1B [invasion of the muscularis propria] and above) receive neoadjuvant or adjuvant therapy in addition to surgery? Outcomes of interest are overall survival (OS), disease-free survival (DFS), and adverse events.